Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2013 · 10-Q
Revenue$82.44M$82.44M+17.1% vs Q2 2012 Net Income$10.48M$10.48M+37.4% vs Q2 2012 EPS Diluted$0.29$0.29+38.1% vs Q2 2012 Operating Income$14,712,000+70.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$26,384,000+170.7% Margins · derivedOperating margin17.8%+5.6 pt vs Q2 2012
Net margin12.7%+1.9 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 6, 2013 · 37 d after period end